Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Receivables (2016 - 2024)

Dare Bioscience (DARE) has disclosed Receivables for 9 consecutive years, with $929982.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables changed N/A year-over-year to $929982.0, compared with a TTM value of $929982.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $929982.0, changed N/A over the prior year.
  • Receivables was $929982.0 for Q4 2024 at Dare Bioscience, down from $12.1 million in the prior quarter.
  • Across five years, Receivables topped out at $52.0 million in Q2 2021 and bottomed at $282560.0 in Q3 2020.
  • Average Receivables over 4 years is $8.5 million, with a median of $893852.0 recorded in 2020.
  • The sharpest move saw Receivables surged 14997.48% in 2021, then tumbled 76.64% in 2022.
  • Year by year, Receivables stood at $472168.0 in 2020, then skyrocketed by 142.57% to $1.1 million in 2021, then surged by 959.76% to $12.1 million in 2022, then crashed by 92.34% to $929982.0 in 2024.
  • Business Quant data shows Receivables for DARE at $929982.0 in Q4 2024, $12.1 million in Q2 2022, and $1.1 million in Q4 2021.